0 9 Increased increase VBN 10 23 proliferation proliferation NN 23 24 , , , 25 37 cytotoxicity cytotoxicity NN 37 38 , , , 39 42 and and CC 43 47 gene gene NN 48 58 expression expression NN 59 64 after after IN 65 76 stimulation stimulation NN 77 79 of of IN 80 85 human human JJ 86 96 peripheral peripheral JJ 97 102 blood blood NN 103 104 T t NN 105 116 lymphocytes lymphocyte NNS 117 124 through through IN 125 126 a a DT 127 134 surface surface NN 135 146 ganglioside ganglioside NN 147 148 ( ( ( 148 151 GD3 GD3 NNP 151 152 ) ) ) 153 154 [ [ ( 154 163 published publish VBN 164 171 erratum erratum NN 172 179 appears appear VBZ 180 182 in in IN 183 184 J J NNP 185 192 Immunol Immunol NNP 193 197 1994 1994 CD 198 201 Jul Jul NNP 202 215 15;153(2):910 15;153(2):910 CD 215 216 ] ] ) 218 226 Previous previous JJ 227 234 studies study NNS 235 239 have have VBP 240 249 suggested suggest VBN 250 254 that that IN 255 267 gangliosides ganglioside NNS 268 272 have have VBP 273 275 an an DT 276 285 important important JJ 286 290 role role NN 291 293 in in IN 294 298 cell cell NN 299 308 signaling signaling NN 309 312 and and CC 313 324 recognition recognition NN 324 325 . . . 326 333 However however RB 333 334 , , , 335 340 their their PRP$ 341 349 specific specific JJ 350 358 function function NN 359 361 in in IN 362 367 these these DT 368 377 processes process NNS 378 381 has have VBZ 382 385 not not RB 386 390 been be VBN 391 398 clearly clearly RB 399 406 defined define VBN 406 407 . . . 408 409 A a DT 410 413 mAb mab NN 413 414 , , , 415 418 R24 R24 NNP 418 419 , , , 420 424 that that WDT 425 431 reacts react VBZ 432 444 specifically specifically RB 445 449 with with IN 450 451 a a DT 452 456 cell cell NN 457 464 surface surface NN 465 476 ganglioside ganglioside NN 477 478 ( ( ( 478 481 GD3 GD3 NNP 481 482 ) ) ) 483 486 has have VBZ 487 491 been be VBN 492 504 demonstrated demonstrate VBN 505 507 to to TO 508 517 stimulate stimulate VB 518 531 proliferation proliferation NN 532 534 of of IN 535 536 T t NN 537 542 cells cell NNS 543 550 derived derive VBN 551 555 from from IN 556 561 human human JJ 562 572 peripheral peripheral JJ 573 578 blood blood NN 578 579 . . . 580 582 In in IN 583 587 this this DT 588 593 study study NN 593 594 , , , 595 597 we we PRP 598 602 have have VBP 603 615 investigated investigate VBN 616 619 the the DT 620 630 mechanisms mechanism NNS 631 633 by by IN 634 639 which which WDT 640 643 the the DT 644 647 R24 r24 NN 648 651 mAb mab NN 652 659 affects affect VBZ 660 661 T t NN 662 666 cell cell NN 667 676 functions function NNS 676 677 . . . 678 680 We we PRP 681 685 have have VBP 686 694 observed observe VBN 695 699 that that IN 700 703 the the DT 704 707 R24 r24 NN 708 711 mAb mab NN 712 722 stimulates stimulate VBZ 723 727 GD3+ gd3+ JJ 728 729 T t NN 730 734 cell cell NN 735 748 proliferation proliferation NN 748 749 , , , 750 762 cytotoxicity cytotoxicity NN 762 763 , , , 764 767 and and CC 768 775 surface surface NN 776 782 marker marker NN 783 793 expression expression NN 794 796 of of IN 797 802 IL-2R IL-2R NNP 803 814 alpha-chain alpha-chain NN 814 815 , , , 816 821 IL-2R IL-2R NNP 822 832 beta-chain beta-chain NN 832 833 , , , 834 840 HLA-DR HLA-DR NNP 840 841 , , , 842 847 CD11a CD11a NNP 847 848 , , , 849 852 and and CC 853 859 CD11c. CD11c. NNP 860 872 Additionally additionally RB 872 873 , , , 874 883 IFN-gamma IFN-gamma NNP 884 892 activity activity NN 893 896 but but CC 897 900 not not RB 901 905 IL-1 il-1 NN 905 906 , , , 907 911 IL-2 il-2 NN 911 912 , , , 913 915 or or CC 916 920 IL-4 il-4 NN 921 929 activity activity NN 930 933 was be VBD 934 941 present present JJ 942 944 in in IN 945 952 culture culture NN 953 965 supernatants supernatant NNS 966 968 72 72 CD 969 970 h h NN 971 976 after after IN 977 980 R24 r24 NN 981 992 stimulation stimulation NN 992 993 . . . 994 996 In in IN 997 1001 some some DT 1002 1008 donors donor NNS 1008 1009 , , , 1010 1019 increased increase VBN 1020 1024 IL-6 IL-6 NNP 1025 1028 and and CC 1029 1038 TNF-alpha TNF-alpha NNP 1039 1047 activity activity NN 1048 1052 also also RB 1053 1056 was be VBD 1057 1065 detected detect VBN 1066 1071 after after IN 1072 1075 R24 r24 NN 1076 1085 treatment treatment NN 1085 1086 . . . 1087 1098 Furthermore furthermore RB 1098 1099 , , , 1100 1103 R24 r24 NN 1104 1113 treatment treatment NN 1114 1122 resulted result VBD 1123 1125 in in IN 1126 1139 translocation translocation NN 1140 1142 of of IN 1143 1148 c-rel c-rel NN 1148 1149 , , , 1150 1153 but but CC 1154 1160 little little JJ 1161 1163 or or CC 1164 1166 no no DT 1167 1169 NF NF NNP 1170 1175 kappa kappa NN 1176 1177 B B NNP 1178 1181 p50 p50 NN 1182 1184 or or CC 1185 1188 p65 p65 NN 1188 1189 , , , 1190 1194 from from IN 1195 1198 the the DT 1199 1208 cytoplasm cytoplasm NN 1209 1211 to to TO 1212 1215 the the DT 1216 1223 nucleus nucleus NN 1224 1227 and and CC 1228 1230 an an DT 1231 1239 increase increase NN 1240 1242 of of IN 1243 1245 NF NF NNP 1246 1251 kappa kappa NN 1252 1253 B B NNP 1254 1261 binding binding NN 1262 1271 complexes complex NNS 1272 1282 containing contain VBG 1283 1288 c-rel c-rel NN 1289 1292 and and CC 1293 1296 p50 p50 NN 1296 1297 . . . 1298 1302 This this DT 1303 1312 treatment treatment NN 1313 1317 also also RB 1318 1324 caused cause VBD 1325 1334 increased increase VBN 1335 1343 tyrosine tyrosine NN 1344 1359 phosphorylation phosphorylation NN 1360 1362 of of IN 1363 1371 specific specific JJ 1372 1379 protein protein NN 1380 1390 substrates substrate NNS 1390 1391 . . . 1392 1406 R24-stimulated r24-stimulated JJ 1407 1416 increases increase NNS 1417 1419 in in IN 1420 1433 proliferation proliferation NN 1433 1434 , , , 1435 1447 cytotoxicity cytotoxicity NN 1447 1448 , , , 1449 1452 and and CC 1453 1457 cell cell NN 1458 1465 surface surface NN 1466 1473 protein protein NN 1474 1484 expression expression NN 1485 1490 could could MD 1491 1493 be be VB 1494 1501 blocked block VBN 1502 1504 by by IN 1505 1516 cyclosporin cyclosporin NN 1517 1520 and and CC 1521 1533 staurosporin staurosporin NN 1533 1534 , , , 1535 1545 indicating indicate VBG 1546 1550 that that IN 1551 1574 cyclophilin/calcineurin cyclophilin/calcineurin NN 1575 1578 and and CC 1579 1586 protein protein NN 1587 1593 kinase kinase NNP 1594 1595 C C NNP 1596 1599 may may MD 1600 1602 be be VB 1603 1611 involved involve VBN 1612 1614 in in IN 1615 1618 the the DT 1619 1622 R24 r24 NN 1623 1632 signaling signaling NN 1633 1640 pathway pathway NN 1640 1641 . . . 1642 1654 Additionally additionally RB 1654 1655 , , , 1656 1666 herbimycin herbimycin NN 1667 1668 A A NNP 1668 1669 , , , 1670 1671 a a DT 1672 1680 tyrosine tyrosine NN 1681 1687 kinase kinase NNP 1688 1697 inhibitor inhibitor NN 1697 1698 , , , 1699 1706 blocked block VBD 1707 1710 the the DT 1711 1725 R24-stimulated r24-stimulated JJ 1726 1734 increase increase NN 1735 1737 in in IN 1738 1751 proliferation proliferation NN 1752 1755 but but CC 1756 1759 not not RB 1760 1772 cytotoxicity cytotoxicity NN 1773 1775 at at IN 1776 1790 concentrations concentration NNS 1791 1801 consistent consistent JJ 1802 1806 with with IN 1807 1818 specificity specificity NN 1819 1822 for for IN 1823 1831 tyrosine tyrosine NN 1832 1839 kinases kinase NNS 1839 1840 . . . 1841 1846 These these DT 1847 1854 results result NNS 1855 1862 suggest suggest VBP 1863 1867 that that IN 1868 1876 multiple multiple JJ 1877 1888 biochemical biochemical JJ 1889 1897 pathways pathway NNS 1898 1901 are be VBP 1902 1910 involved involve VBN 1911 1913 in in IN 1914 1917 the the DT 1918 1928 activation activation NN 1929 1931 of of IN 1932 1937 human human JJ 1938 1939 T t NN 1940 1945 cells cell NNS 1946 1948 by by IN 1949 1952 R24 r24 NN 1952 1953 . . .